Insiders · CADL

Mark E. Sims

Chief Commercial Officer at Candel Therapeutics, Inc. (CADL) since July 2026

Mark E. Sims has filed 2 insider reports with the SEC since July 2026, as chief Commercial Officer at Candel Therapeutics, Inc. (CADL). The latest filing, on July 8, 2026, reports grant or award at Candel Therapeutics, Inc. (CADL).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Mark E. Sims is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Candel Therapeutics, Inc. logo
CADL
Candel Therapeutics, Inc.
Chief Commercial Officersince July 2026$9.35Jul 8, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark E. Sims with

Other insiders at the same companies

Questions about Mark E. Sims

What is Mark E. Sims's role at Candel Therapeutics, Inc.?
Mark E. Sims reports to the SEC as chief Commercial Officer at Candel Therapeutics, Inc. (CADL), according to the latest filing on July 8, 2026.
Has Mark E. Sims bought or sold stock recently?
No open-market purchases or sales by Mark E. Sims are on file. The filings report grant or award.
How do I get alerts when Mark E. Sims files?
Follow Mark E. Sims on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark E. Sims (SEC CIK 0002139479). Totals count each trade once, skipping amendments whose original is on file, from Jul 8, 2026 on. View on SEC EDGAR